B-9972 (D-Arg-[Hyp3,Igl5,Oic7,Igl 8]-bradykinin) is an inactivation-resistant agonist of the bradykinin B2 receptor derived from the peptide antagonist B-9430 (D-Arg-[Hyp3,Igl5,D-Igl7,Oic 8]-bradykinin): Pharmacologic profile and effective induction of receptor degradation

Journal of Pharmacology and Experimental Therapeutics

Volumn 323, Issue 2, 2007, Pages 534-546

  Bawolak, Marie Thérèse ^a   Gera, Lajos ^b   Morissette, Guillaume ^a   Stewart, John M ^b   Marceau, François ^a  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B 9430; B 9972; BRADYKININ; BRADYKININ B2 RECEPTOR; GREEN FLUORESCENT PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BINDING ASSAY; CHEMICAL STRUCTURE; DEGRADATION; ENDOCYTOSIS; HUMAN; HUMAN CELL; IMAGING; IMMUNOBLOTTING; NONHUMAN; PHOSPHORYLATION; PRIORITY JOURNAL; RAT; STEREOCHEMISTRY;

ANIMALS; BRADYKININ; CERCOPITHECUS AETHIOPS; COS CELLS; DOSE-RESPONSE RELATIONSHIP, DRUG; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; MALE; OLIGOPEPTIDES; PHOSPHORYLATION; RABBITS; RADIOLIGAND ASSAY; RECEPTOR, BRADYKININ B2; VASOCONSTRICTION;

EID: 35548973922     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.107.123422     Document Type: Article

References (40)

1. 2 receptor endocytosis, recycling, and down-regulation assessed using green fluorescent protein conjugates. J Pharmacol Exp Ther 297:19-26.
2. 2 receptor. J Pharmacol Exp Ther 275:1623-1630.
3. Bawolak MT and Marceau F (2007) Does zaltoprofen antagonize the bradykinin receptors? Regul Pept 140:125-130.
4. Bironaite D, Gera L, and Stewart JM (2004) Characterization of the B2 receptor and activity of bradykinin analogs in SHP-77 cell line by Cytosensor microphysiometer. Chem Biol Interact 150:283-293.
5. Blaukat A, Abd Alla S, Lohse MJ, and Müller-Esterl W (1996) Ligand-induced phosphorylation/dephosphorylation of the endogenous bradykinin B2 receptor from human fibroblasts. J Biol Chem 271:32366-32374.
6. 2 receptor in vivo phosphorylation sites and their role in receptor function. J Biol Chem 276:40431-40440.
7. 2 receptor in a tetracycline-inducible stable HEK293S cell line. Protein Expr Purif 55:300-311.
8. Chan D, Gera L, Stewart J, Helfrich B, Verella-Garcia M, Johnson G, Baron A, Yang J, Puck T, and Bunn P Jr (2002) Bradykinin antagonist dimer, CU201, inhibits the growth of human lung cancer cell lines by a "biased agonist" mechanism. Proc Natl Acad Sci U S A 99:4608-4613.
9. 2 receptor selective agonist which is not broken down by either kininase I or kininase II. Eur J Pharmacol 155:193-195.
10. 1 receptors in cultured cells. Am J Physiol 284:H1647-H1654.
11. 1 receptor. Mol Pharmacol 69:1146-1157.
12. 1 receptors in the rabbit aorta. J Pharmacol Exp Ther 314:1169-1174.
13. Fortin JP and Marceau F (2006) Advances in the development of bradykinin receptor ligands. Curr Topics Med Chem 6:1353-1363.
14. Gaudreau P, Barabé J, St-Pierre S, and Regoli D (1981) Pharmacological studies of kinins in venous smooth muscle. Can J Physiol Pharmacol 59:371-379.
15. Gera L and Stewart JM (1996) A new class of bradykinin antagonists containing indanylglycine. Immunopharmacology 33:174-177.
16. Gera L, Stewart JM, Whalley E, Burkard M, and Zuzack JS (1996) A new class of potent bradykinin antagonist dimers. Immunopharmacology 33:178-182.
17. 2 receptor. Hypertension 35:1319-1325.
18. 2 receptor: role of phosphatidylinositol-3 kinase and Rab5. Biochem J 375:151-158.
19. Houle S, Molinaro G, Adam A, and Marceau F (2003) Tissue kallikrein actions at the rabbit natural or recombinant kinin B2 receptors. Hypertension 41:611-617.
20. Jarnagin K, Bhakta S, Zuppan P, Yee C, Ho T, Phan T, Tahilramani R, Pease JH, Miller A, and Freedman R (1996) Mutations in the B2 bradykinin receptor reveal a different pattern of contacts for peptidic agonists and peptidic antagonists. J Biol Chem 271:28277-28286.
21. 2 receptor strongly affects down-regulation but not receptor internalization or signaling. Biol Chem 387:603-610.
22. Leeb-Lundberg LMF, Marceau F, Müller-Esterl W, Pettibone DJ, and Zuraw BL (2005) International Union of Pharmacology: XLV. Classification of the kinin receptor family: from molecular mechanisms to pathophysiological consequences. Pharmacol Rev 57:27-77.
23. 2 receptor. Int Immunopharmacol 3:1529-1536.
24. 2 receptor. Peptides 22:1397-1402.
25. 2 receptors on the venoconstrictor action of bradykinin. J Pharmacol Exp Ther 269:1136-1143.
26. Marceau F, Sabourin T, Houle S, Fortin JP, Petitclerc E, Molinaro G, and Adam A (2002) Kinin receptors: Functional aspects. Int Immunopharmacol 2:1729-1739.
27. Moore RH, Tuffaha A, Millman EE, Dai W, Hall HS, and Dickey BF (1999) Agonist-induced sorting of human β2-adrenergic receptors to lysosomes during downregulation. J Cell Sci 112:329-339.
28. 2 receptors. Br J Pharmacol 150:369-379.
29. Munoz CM and Leeb-Lundberg LMF (1992) Receptor-mediated internalization of bradykinin. DDT1 MF-2 smooth muscle cells process internalized bradykinin via multiple degradation pathways. J Biol Chem 267:303-309.
30. Oksche A, Boese G, Horstmeyer A, Furkert J, Beyermann M, Bienert M, and Rosenthal W (2000) Late endosomal/lysosomal targeting and lack of recycling of the ligand-occupied endothelin B receptor. Mol Pharmacol 57:1104-1113.
31. Pan W, Kastin AJ, Gera L, and Stewart JM (2001) Bradykinin antagonist decreases early disruption of the blood-spinal cord barrier after spinal cord injury in mice. Neurosci Lett 307:25-28.
32. Prechel MM, Orawski AT, Maggiora LL, and Simmons WH (1995) Effect of a new aminopeptidase P inhibitor, apstatin, on bradykinin degradation in the rat lung. J Pharmacol Exp Ther 275:1136-1142.
33. 2 receptor antagonist. Immunopharmacology 43:187-194.
34. 2 receptor antagonist: an in vitro study. Hypertension 29:951-956.
35. Stewart JM, Gera L, Chan DC, Bunn PA, York EJ, Simkeviciene V, and Helfrich B (2002) Bradykinin-related compounds as new drugs for cancer and inflammation. Can J Physiol Pharmacol 80:275-280.
36. Stewart JM, Gera L, Hanson W, Zuzack JS, Burkard M, McCullough R, and Whalley ET (1996) A new generation of bradykinin antagonists. Immunopharmacology 33:51-60.
37. Taraseviciene-Stewart L, Scerbavicius R, Stewart JM, Gera L, Demura Y, Cool C, Kasper M, and Voelkel NF (2005) Treatment of severe pulmonary hypertension: a bradykinin receptor 2 agonist B9972 causes reduction of pulmonary artery pressure and right ventricular hypertrophy. Peptides 26:1292-1300.
38. Thomas SM, Bhola NE, Zhang Q, Contrucci SC, Wentzel AL, Freilino M, Gooding WE, Siegfried JM, Chan DC, and Grandis JR (2006) Cross-talk between G protein-coupled receptor and epidermal growth factor receptor signaling pathways contributes to growth and invasion of head and neck squamous cell carcinoma. Cancer Res 66:11831-11839.
39. Uknis AB, de la Cadena RA, Janardham R, Sartor RB, Whalley ET, and Colman RW (2001) Bradykinin receptor antagonists type 2 attenuate the inflammatory changes in peptidoglycan-induced acute arthritis in the Lewis rat. Inflamm Res 50:140-155.
40. Vavrek RJ and Stewart JM (1985) Competitive antagonists of bradykinin. Peptides 6:161-164.